Evaluating the role of phase I expansion cohorts in oncologic drug development

Conclusion The importance of including an EC in phase I trials is subject to ongoing debate. Our results demonstrated little benefit to including EC in phase I studies. These findings support that innovative design strategies are needed to optimize the utility of EC in phase I studies.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research